A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

NCT06864143 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1320

Last updated 2025-10-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.

Conditions

Interventions

BIOLOGICAL

mRNA-1083 Composition 1 Dose A Lot A

Sterile liquid for injection

BIOLOGICAL

mRNA-1083 Composition 1 Dose A Lot B

Sterile liquid for injection

BIOLOGICAL

mRNA-1083 Composition 1 Dose B

Sterile liquid for injection

BIOLOGICAL

mRNA-1083 Composition 1 Dose C

Sterile liquid for injection

BIOLOGICAL

mRNA-1083 Composition 2 Dose A

Sterile liquid for injection

BIOLOGICAL

mRNA-1083 Composition 2 Dose B

Sterile liquid for injection

BIOLOGICAL

mRNA-1083 Composition 3 Dose A

Sterile liquid for injection

BIOLOGICAL

mRNA-1083 Composition 3 Dose B

Sterile liquid for injection

BIOLOGICAL

Influenza Vaccine

Sterile liquid for injection

BIOLOGICAL

COVID-19 Vaccine

Sterile liquid for injection

BIOLOGICAL

Investigational Influenza Vaccine

Sterile liquid for injection

BIOLOGICAL

Investigational COVID-19 Vaccine Lot A

Sterile liquid for injection

BIOLOGICAL

Investigational COVID-19 Vaccine Lot B

Sterile liquid for injection

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-07
Primary Completion
2025-10-13
Completion
2025-10-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06864143 on ClinicalTrials.gov